Latanoprost Viatris (Latanoprost)

Latanoprost activates prostaglandin F‑type receptors in the eye, which increases uveoscleral outflow of aqueous humor. This enhanced drainage lowers intra‑ocular pressure, addressing the primary cause of glaucoma‑related vision loss.

The prescribed regimen is determined by the treating ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dosing schedule should follow the clinician’s instructions.

Safety data for Latanoprost in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the prescribing physician.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong pressure‑lowering efficacy. Compared with beta‑blocker drops like timolol, prostaglandin analogs often have a more favorable dosing schedule and comparable or greater IOP reduction, though individual response may vary.

Store the ophthalmic solution at room temperature, below 25 °C, in its original container. Protect it from direct light and moisture, and keep the bottle tightly closed when not in use to maintain sterility.

Latanoprost is applied as a single drop into the conjunctival sac of the affected eye(s) once daily, preferably in the evening. The patient should wash hands before use, avoid touching the tip to the eye or any surface, and gently close the eye for a few minutes after instillation.

Serious adverse events, though rare, include severe eye inflammation such as uveitis, allergic reactions that may involve swelling or rash, and sudden vision loss. Any of these symptoms require immediate medical evaluation.

Latanoprost is contraindicated in patients with known hypersensitivity to the drug or any component of the formulation. It should also be avoided in eyes with active intra‑ocular infection or inflammation until the condition is resolved.